Levodopa in the treatment of Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of neural transmission. Supplementum

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-211-33328-0_1PMID 17447410
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson’s Disease

  2012cited by this paper
• Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study

  2005cited by this paper
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• Atypical cancer pattern in patients with Parkinson's disease

  2004cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

  2004cited by this paper
• Initial agonist treatment of Parkinson disease

  2003cited by this paper
• Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

  2003cited by this paper
• Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?

  2003cited by this paper
• Survival study of Parkinson disease in Olmsted County, Minnesota.

  2003cited by this paper
• Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study

  2003cited by this paper
• Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.

  2002cited by this paper
• Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.

  2002cited by this paper
• Risk tables for parkinsonism and Parkinson's disease.

  2002cited by this paper
• Do dopamine agonists or levodopa modify Parkinson's disease progression?

  2002cited by this paper
• Influence of strict, intermediate, and broad diagnostic criteria on the age‐ and sex‐specific incidence of Parkinson's disease

  2000cited by this paper
• The initial treatment of Parkinson's disease.

  2000cited by this paper
• The initial treatment of Parkinson's disease

  2000cited by this paper
• [Lewy bodies].

  2000cited by this paper
• Levodopa Therapy and the Risk of Malignant Melanoma

  2000cited by this paper
• A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

  2000cited by this paper
• The long-duration response to l-dopa in the treatment of early PD

  2000cited by this paper
• Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake

  2000cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

  2000cited by this paper
• Parkinson disease in twins: an etiologic study.

  1999cited by this paper
• The initial treatment of Parkinson's disease should begin with levodopa

  1999cited by this paper
• Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

  1999cited by this paper
• Immediate-release and controlled-release carbidopa/levodopa in PD

  1999cited by this paper
• Quality of life and Parkinson’s disease: The CR FIRST Study

  1998cited by this paper
• [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

  1998cited by this paper
• Poster Presentation Floor Plan

  1998cited by this paper
• Early Treatment of Parkinson’s Disease with Cabergoline Delays the Onset of Motor Complications

  1998cited by this paper
• Levodopa: Is toxicity a myth?

  1998cited by this paper
• Implications of the 5-year CR FIRST trial

  1998cited by this paper
• Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature.

  1997cited by this paper
• Levodopa-Induced Neurotoxicity

  1997cited by this paper
• Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease.

  1997cited by this paper
• Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

  1997cited by this paper
• An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

  1996cited by this paper
• Is levodopa toxic?

  1996cited by this paper
• Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease

  1995cited by this paper
• Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET.

  1995cited by this paper
• Safety of Long‐term Levodopa Therapy in Malignant Melanoma

  1994cited by this paper
• Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism

  1994cited by this paper
• A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

  1994cited by this paper
• Risk factors for nursing home placement in advanced Parkinson's disease

  1993cited by this paper
• Levodopa, melanoma, and Parkinson's disease

  1993cited by this paper
• “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease

  1991cited by this paper
• The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa

  1991cited by this paper
• Response fluctuations in Parkinson's disease

  1990cited by this paper
• Which risk factors predict the levodopa response in fluctuating Parkinson's disease?

  1990cited by this paper
• Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease

  1990cited by this paper
• Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1989cited by this paper
• Parkinsonian Symptomatology An Anatomical and Physiological Analysisa a

  1988cited by this paper
• Does levodopa aggravate Parkinson's disease?

  1988cited by this paper
• Young onset Parkinson's disease

  1987cited by this paper
• Factors that influence the occurrence of response variations in Parkinson's disease

  1987cited by this paper
• Low‐dose L‐dopa therapy in Parkinson's disease

  1986cited by this paper
• Long‐term follow‐up of early dopa treatment in Parkinson's disease

  1986cited by this paper
• Striatal inhomogeneities and basal ganglia function

  1986cited by this paper
• Levodopa and melanoma: three cases and review of literature.

  1985cited by this paper
• Development of two malignant melanomas during administration of levodopa.

  1985cited by this paper
• Fluctuations of disability in Parkinson's disease – clinical aspects

  1981cited by this paper
• Problems in Parkinson's disease

  1981cited by this paper
• Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease.

  1979cited by this paper
• Levodopa therapy and malignant melanoma.

  1978cited by this paper
• Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.

  1977cited by this paper
• "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

  1976cited by this paper
• Levodopa-induced myoclonus.

  1975cited by this paper
• Patterns of clinical response and plasma dopa levels in Parkinson's disease

  1975cited by this paper
• Variations in the "on-off" phenomenon.

  1974cited by this paper
• Variations in the "on-off" phenomenon.

  1974cited by this paper
• The "on-off" response to chronic L-DOPA treatment of Parkinsonism.

  1974cited by this paper
• Variations in the "on-off" effect.

  1974cited by this paper
• “On‐off” phenomenon with levodopa therapy in parkinsonism

  1974cited by this paper
• Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

  1973cited by this paper
• Multiple primary melanoma following administration of levodopa.

  1972cited by this paper
• L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

  1971cited by this paper
• Newer medical treatment in parkinsonism.

  1970cited by this paper
• Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).

  1970cited by this paper
• Modification of Parkinsonism--chronic treatment with L-dopa.

  1969cited by this paper
• Treatment of parkinsonism with levodopa.

  1969cited by this paper
• AN ESSAY ON THE SHAKING PALSY

  1969cited by this paper
• A double blind study of 1-dopa treatment in Parkinson's disease.

  1968cited by this paper
• A Double Blind Study of l-Dopa Treatment in Parkinson's Disease

  1968cited by this paper
• [What success does L-Dopa have in the treatment of parkinsonian akinesia?].

  1967cited by this paper
• The prevention of acute gastric ulcer in the rat by alpha-methyldopa.

  1967cited by this paper
• Parkinsonism

  1967cited by this paper
• Was leistet L-Dopa bei der Behandlung der Parkinson-Akinese?*

  1967cited by this paper
• Aromatic amino acids and modification of parkinsonism.

  1967cited by this paper
• TREATMENT OF PARKINSON'S SYNDROME WITH L‐DOPA A DOUBLE BLIND STUDY

  1966cited by this paper
• Treatment of Parkinson's syndrome with L-dopa. A double blind study.

  1966cited by this paper
• Zur Beeinflussung der Akinese und anderer extrapyramidal-motorischer Störungen mit L-Dopa (L-Dihydroxyphenylalanin)

  1964cited by this paper
• ADMINISTRATION OF DIHYDROXYPHENYLALANINE TO PARKINSONIAN PATIENTS.

  1964cited by this paper
• Die Wirksamkeit von L-Dopa bei Parkinson-Patienten mit und ohne stereotaktischen Hirneingriff

  1964cited by this paper
• [ON THE CONTROL OF AKINESIA AND OTHER EXTRAPYRAMIDAL MOTOR DISORDERS WITH L-DOPA (L-DIHYDROXYPHENYLALANINE)].

  1964cited by this paper
• Dopamine metabolism in Parkinson's disease

  1963cited by this paper
• Dihydroxyphenylalanine in extrapyramidal disease.

  1963cited by this paper
• [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

  1961cited by this paper
• Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.

  1960cited by this paper
• 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists

  1957cited by this paper

• Parkinson’s disease medication adjustments based on wearable device information compared to other methods: randomized clinical trial

  2025cites this paper
• Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression

  2025cites this paper
• Neuroprotective effect of L-DOPA-induced interleukin-13 on striatonigral degeneration in cerebral ischemia

  2024cites this paper
• A voltammetric method coupled with chemometrics for determination of a ternary antiparkinson mixture in its dosage form: greenness assessment

  2024cites this paper
• Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease

  2024cites this paper
• Prevalence of radicular neuropathic pain in idiopathic Parkinson's disease: a systematic review and meta-analysis.

  2024cites this paper
• Associations between gut microbiota characteristics and non‐motor symptoms following pharmacological and surgical treatments in Parkinson's disease patients

  2024cites this paper
• Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease

  2023cites this paper
• The Early Treatment Phase in Parkinson’s Disease: Not a Honeymoon for All, Not a Honeymoon at All?

  2023cites this paper
• The role of dopamine in NLRP3 inflammasome inhibition: implications for neurodegenerative diseases.

  2023cites this paper
• Comparison of the Results of a Parkinson's Holter Monitor With Patient Diaries, in Real Conditions of Use: A Sub-analysis of the MoMoPa-EC Clinical Trial

  2022cites this paper
• Chinese herbal medicine treatment based on subgroup differentiation as adjunct therapy for Parkinson’s disease: study protocol of a pilot add-on, randomised, controlled, pragmatic clinical trial

  2022cites this paper
• Dopamine neuron stimulation induces context-dependent abnormal involuntary movements in healthy rats

  2022cites this paper
• Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?

  2022cites this paper
• Modeling Polyzwitterion-Based Drug Delivery Platforms: A Perspective of the Current State-of-the-Art and Beyond

  2022cites this paper
• Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs

  2021cites this paper
• Inclusion of Levodopa into β-Cyclodextrin: A Comprehensive Computational Study

  2021cites this paper
• How far can I reach? The perception of upper body action capabilities in Parkinson’s disease

  2021cites this paper
• Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain

  2020cites this paper
• Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson’s disease rat model

  2020cites this paper
• Current Status of Stem Cell-Derived Therapies for Parkinson’s Disease: From Cell Assessment and Imaging Modalities to Clinical Trials

  2020cites this paper
• Extended-Release Amantadine for Levodopa-Induced Dyskinesia

  2019cites this paper
• RETRACTED: Fabrication, Optimization, and Evaluation of Rotigotine-Loaded Chitosan Nanoparticles for Nose-To-Brain Delivery

  2019cites this paper
• Commentary: Trends in the Use of Deep Brain Stimulation for Parkinson Disease

  2018cites this paper
• Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.

  2018cites this paper
• Long-term management of Parkinson’s disease using levodopa combinations

  2018cites this paper
• Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort

  2018cites this paper
• Dibutyltin(IV) Complexes Derived from L-DOPA: Synthesis, Molecular Docking, Cytotoxic and Antifungal Activity.

  2018cites this paper
• Cyclodextrins in Parkinson’s Disease

  2018cites this paper
• Levodopa in Parkinson’s Disease: Current Status and Future Developments

  2017cites this paper
• Advanced research on deep brain stimulation in treating mental disorders.

  2017cites this paper
• Horseradish peroxidase-catalyzed polymerization of L-DOPA for mono-/bi-enzyme immobilization and amperometric biosensing of H2O2 and uric acid.

  2016cites this paper
• Do we need a new levodopa?

  2016cites this paper
• Nonmotor symptoms in Parkinson's disease: are we still waiting for the honeymoon?

  2016cites this paper
• Unmasking the Effects of L-DOPA on Rapid Dopamine Signaling with an Improved Approach for Nafion Coating Carbon-Fiber Microelectrodes.

  2016cites this paper
• Disparities in deep brain stimulation surgery among insured elders with Parkinson disease

  2014cites this paper
• Safinamide for the treatment of Parkinson’s disease

  2014cites this paper
• Disparities in deep brain stimulation surgery among insured elders with Parkinson disease

  2014cites this paper
• [Medical treatment of Parkinson's disease in elderly and multimorbid patients].

  2014cites this paper
• Novel perspectives for Parkinson's disease therapy: insights from the latest advances in disease pathophysiology, diagnostic and experimental tools and molecular targets.

  2013cites this paper
• Co-Transplantation of GDNF-Overexpressing Neural Stem Cells and Fetal Dopaminergic Neurons Mitigates Motor Symptoms in a Rat Model of Parkinson’s Disease

  2013cites this paper
• Subthalamic hGAD65 Gene Therapy and Striatum TH Gene Transfer in a Parkinson’s Disease Rat Model

  2013cites this paper
• Nanotechnology-Based Drug Delivery Systems for Targeting, Imaging and Diagnosis of Neurodegenerative Diseases

  2013cites this paper
• Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.

  2013cites this paper
• Targeting Caspase-3 as Dual Therapeutic Benefits by RNAi Facilitating Brain-Targeted Nanoparticles in a Rat Model of Parkinson’s Disease

  2013cites this paper
• The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.

  2013cites this paper
• Medication and subthalamic nucleus deep brain stimulation similarly improve balance and complex gait in Parkinson disease.

  2013cites this paper
• Gene therapy for Parkinson’s disease: state-of-the-art treatments for neurodegenerative disease

  2013cites this paper
• L-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro.

  2012cites this paper
• Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson’s disease in the MPTP-induced mice model

  2012cites this paper
• The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.

  2012cites this paper
• Medication improves balance and complex gait performance in Parkinson disease.

  2012cites this paper
• Gene Therapy for Parkinson's Disease

  2012cites this paper
• Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease

  2012cites this paper
• New non-oral drug delivery systems for Parkinson's disease treatment

  2011cites this paper
• Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug.

  2011cites this paper
• L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?

  2011cites this paper
• In Silico Design of a Peptidomimetic Carrier for Levodopa

  2011cites this paper
• The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease

  2011cites this paper
• Proteins containing oxidized amino acids induce apoptosis in human monocytes.

  2011cites this paper
• A Web-Based System for Home Monitoring of Patients With Parkinson's Disease Using Wearable Sensors

  2011cites this paper
• Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.

  2010cites this paper
• Voice onset time in Parkinson disease.

  2010cites this paper
• Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.

  2010cites this paper
• Levodopa delivery systems for the treatment of Parkinson's disease: an overview.

  2009cites this paper
• Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats

  2009cites this paper
• Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.

  2009cites this paper
• Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson’s disease

  2009cites this paper
• [Optimisation of treatment of Parkinson's disease with levodopa].

  2009cites this paper
• New insights into the organization of the basal ganglia

  2009cites this paper
• Preclinical development of gene therapy for Parkinson's disease.

  2008cites this paper
• The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease

  2008cites this paper
• Drugs used to treat Parkinson's disease, present status and future directions.

  2008cites this paper
• Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities

  2008cites this paper
• Levodopa and executive performance in Parkinson's disease: A randomized study

  2008cites this paper
• The mitochondrial free radical theory of ageing--where do we stand?

  2008cites this paper
• Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.

  2007cites this paper
• Restorative cell therapy for Parkinson's disease: a quest for the perfect cell.

  2007cites this paper